AMPD1 Antibody

What is AMPD1 and what is its biological function?

AMPD1, also known as MAD and MADA, belongs to the adenosine and AMP deaminases family. It plays a critical role in energy metabolism by catalyzing the conversion of adenosine monophosphate (AMP) to inosine monophosphate (IMP) through the reaction: AMP + H₂O = IMP + NH₃ . This enzyme is primarily expressed in skeletal muscle tissue and is involved in the purine nucleotide cycle. Defects in AMPD1 are associated with adenosine monophosphate deaminase deficiency, a metabolic disorder affecting muscle energy production .

The gene is located on chromosome 1 and encodes a protein with a calculated molecular weight of 87 kDa, although it typically appears at 75-83 kDa in Western blot applications due to post-translational modifications . Understanding AMPD1's function is essential for research in metabolic disorders, muscle physiology, and increasingly, in cancer biology.

What are the common applications for AMPD1 antibodies in research?

AMPD1 antibodies can be utilized across multiple experimental platforms:

When designing experiments, researchers should note that AMPD1 is most abundantly expressed in skeletal muscle tissue, making this an optimal positive control for antibody validation . Additionally, careful optimization of antibody concentration is recommended for each specific experimental system to obtain optimal results.

What species reactivity do commonly available AMPD1 antibodies demonstrate?

Available AMPD1 antibodies show cross-reactivity with multiple species, which is important for comparative studies and selecting appropriate experimental models:

When planning experiments with animal models or human samples, verifying the specific reactivity of your selected antibody is crucial. Many commercial antibodies are raised against conserved epitopes, explaining their broad cross-reactivity across species. For example, the ABIN372278 antibody targets amino acids 500-550 of human AMPD1, a region with high conservation across vertebrates .

What is the recommended storage protocol for AMPD1 antibodies?

For optimal antibody performance and longevity, follow these storage recommendations:

• Store antibodies at -20°C for long-term storage

• Most AMPD1 antibodies are stable for one year after shipment when properly stored

• Antibodies are typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting is generally unnecessary for -20°C storage, reducing freeze-thaw cycles

• Some preparations may contain 0.1% BSA as a stabilizer

Proper storage conditions help maintain antibody integrity and specificity, ensuring reliable experimental results over time. Always check manufacturer-specific recommendations, as formulations may vary between suppliers.

What is the optimal protocol for AMPD1 detection by immunohistochemistry?

For successful immunohistochemical detection of AMPD1 in tissue sections:

• Recommended dilution range: 1:50-1:500 for paraffin-embedded tissues

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Positive control tissue: Skeletal muscle shows consistent AMPD1 expression

• Detection system: Standard HRP-conjugated secondary antibody systems are compatible

• Counterstaining: Hematoxylin provides good nuclear contrast

When performing IHC studies comparing normal and pathological tissues, serial sections should be used to ensure consistency across different antibody stainings. This approach was successfully employed in studies examining AMPD1, CD4, and CD8 co-expression in breast cancer samples .

How does AMPD1 expression differ between normal and cancer tissues?

Research has revealed significant differences in AMPD1 expression between normal and malignant tissues:

• In HER2-positive breast cancer:

  • AMPD1 expression is markedly lower in tumor tissues compared to adjacent normal tissues

  • Immunohistochemical analyses confirm suppressed AMPD1 protein expression in cancerous tissues

• In papillary thyroid carcinoma (PTC):

  • Downregulated AMPD1 expression has been observed in patient serum samples

  • Expression levels correlate with tumor diameter and TNM stage

These differential expression patterns suggest AMPD1 could serve as a potential tissue biomarker. When designing studies to investigate AMPD1 expression, inclusion of matched tumor and adjacent normal tissues provides the most reliable comparative data.

What are the expected molecular weight and band patterns for AMPD1 in Western blotting?

When performing Western blot analysis of AMPD1:

• Calculated molecular weight: 87 kDa

• Observed molecular weight range: 75-83 kDa

• Recommended positive control: Mouse skeletal muscle tissue

• Recommended dilution range: 1:500-1:3000

The discrepancy between calculated and observed molecular weights likely results from post-translational modifications or alternative splicing. When troubleshooting Western blots, ensure adequate protein loading (20-30 μg total protein) and optimize transfer conditions for high-molecular-weight proteins.

How can researchers validate the specificity of AMPD1 antibodies?

To verify AMPD1 antibody specificity and minimize experimental artifacts:

• Positive controls:

  • Use skeletal muscle tissue samples which consistently express AMPD1

  • Include recombinant AMPD1 protein when available

• Negative controls:

  • Employ AMPD1 knockout/knockdown samples for definitive validation

  • Published literature confirms successful use of KD/KO approaches for AMPD1 antibody validation

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide (corresponding to amino acids 500-550 for some antibodies)

  • Signal elimination confirms specificity

• Multiple detection methods:

  • Cross-validate findings using different application techniques (WB, IHC, IP)

  • Consistent results across platforms strengthen confidence in specificity

Antibody validation is crucial for ensuring reproducible results in AMPD1 research. Published studies have successfully used knockdown/knockout approaches to confirm antibody specificity, as noted in the literature cited for specific antibodies .

How is AMPD1 expression associated with tumor-infiltrating immune cells?

AMPD1 demonstrates significant correlations with specific immune cell populations in the tumor microenvironment:

• Positive associations with:

  • CD4+ memory resting T cells

  • CD4+ memory activated T cells

  • CD8+ T cells

  • Gamma delta T cells

  • M1 macrophages

  • Plasma cells

• Negative associations with:

  • M0 macrophages

  • M2 macrophages

These correlations were established using the CIBERSORT algorithm to evaluate immune cell fractions in HER2+ breast cancer samples . Importantly, immunohistochemical analyses have confirmed co-expression of AMPD1 with CD4 and CD8 in clinical samples, providing validation beyond computational approaches .

When investigating tumor immune microenvironment, researchers should consider multiplex immunohistochemistry or flow cytometry to further validate these associations in their specific cancer models.

What signaling pathways are enriched in samples with high AMPD1 expression?

Gene Set Enrichment Analysis (GSEA) has revealed that high AMPD1 expression correlates with enrichment of specific immune-related pathways:

• HALLMARK gene sets enriched in high AMPD1 samples:

  • TNFα signaling pathway

  • Interleukin family signaling

  • Interferon response pathways

• C7 collection (immunologic signature gene sets):

  • Multiple immune functional gene sets show enrichment in samples with upregulated AMPD1

These findings suggest AMPD1 may be functionally involved in immune response regulation. Researchers investigating AMPD1's role in cancer should consider incorporating pathway analysis and immune profiling in their experimental design to better understand the mechanistic contributions of this enzyme.

What is the prognostic significance of AMPD1 expression in cancer?

AMPD1 expression has demonstrated potential as a prognostic biomarker:

When designing studies to evaluate AMPD1 as a prognostic marker, researchers should employ multivariate analysis to account for confounding factors and consider correlation with established prognostic indicators for the specific cancer type being studied.

How might AMPD1 contribute to cancer immunology and checkpoint therapy?

AMPD1's role in cancer immunology appears multifaceted:

• Metabolic influence:

  • AMPD1 catalyzes AMP conversion to IMP, potentially affecting adenosine levels in the tumor microenvironment

  • Adenosine is a known immunosuppressive molecule in the TME

• Checkpoint therapy connections:

  • Positive correlation between AMPD1 and PD-L1/PD-L2 expression in HER2+ breast cancer

  • PD-L1 and PD-L2 are established targets for immune checkpoint inhibitor therapy

• Immune cell association:

  • AMPD1 positively correlates with beneficial immune cell populations (CD8+ T cells, M1 macrophages)

  • These populations are typically associated with better immunotherapy response

These connections suggest that AMPD1 could potentially serve as a biomarker for immunotherapy response. Researchers investigating this possibility should consider examining AMPD1 expression in cohorts treated with checkpoint inhibitors and analyze correlation with treatment outcomes.

What methodological approaches are recommended for studying AMPD1's functional role in immune regulation?

To investigate AMPD1's functional contribution to immune regulation:

• Genetic manipulation approaches:

  • CRISPR/Cas9-mediated knockout in cell lines or mouse models

  • siRNA or shRNA knockdown for transient expression reduction

  • Overexpression systems using lentiviral vectors

• Functional assays:

  • T cell proliferation and activation assays in the presence of AMPD1-modulated cells

  • Macrophage polarization studies (M1 vs. M2) with AMPD1 manipulation

  • Metabolite profiling focusing on adenosine pathway intermediates

• In vivo modeling:

  • Syngeneic mouse models with AMPD1 knockout/overexpression

  • Analysis of tumor growth and immune infiltration

  • Response to checkpoint inhibitor therapy in AMPD1-modified models

• Clinical correlation studies:

  • Multi-parameter immunohistochemistry for AMPD1, CD4, CD8, and checkpoint molecules

  • Correlation with treatment response and patient outcomes

These approaches can help establish whether AMPD1's associations with immune parameters are correlative or causal, advancing understanding of its potential as a therapeutic target or biomarker.